HAIC of OXA
ApprovedSmall molecule
HAIC of OXA is one of 55 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Approved.
2
Indications
7
Total Trials
2
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
797 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1HAIC of OXA
SSun Yat-sen University
Approved
Cysteine Hydrochloride
NovartisPreclinical
Viread
GileadPreclinical
Ibrance
PfizerPreclinical
Hepsera
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Statin
Bristol-Myers SquibbPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sorafenib2 trials
Unresectable1 trial
Hepatocellular Carcinoma1 trial
Intrahepatic Cholangiocarcinoma1 trial
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Recruiting·—·Phase 4·NCT05124002·66 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HAIC of OXA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSun Yat-sen University